| abstract |
The present invention provides a composition for detecting a biomarker for predicting the osteodifferentiation ability of tonsil-derived mesenchymal stem cells comprising an agent for measuring the expression level of the mRNA or protein of the present WNT16. WNT16, a biomarker according to the present invention, provides information on the osteodifferentiation ability of stem cells themselves so as to solve the problem of heterogeneity due to undifferentiated stem cells, in particular, combinations of cells of various precursor cells. Through this, it is possible to determine the induction of bone differentiation of appropriate stem cells, and it can be used to develop tonsil-derived mesenchymal stem cell-based therapeutics using bone-related cells. |